PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United States. The company is headquartered in Laguna Hills, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -8.24% |
| Return on Assets | -6.75% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.59 |
| Price-to-Book | 0.19 |
| Price-to-Sales (TTM) | 12904.41 |
| EV/Revenue | 14270.44 |
| EV/EBITDA | -12.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $10.74M |
| Float | $9.96M |
| % Insiders | 5.74% |
| % Institutions | 9.17% |
Volatility is currently contracting